Literature DB >> 27299798

Spindle Cell Melanoma and Interdigitating Dendritic Cell Sarcoma: Do They Represent the Same Process?

Anne M Stowman1, Stacey E Mills, Mark R Wick.   

Abstract

Intranodal spindle cell lesions on biopsy are problematic for a surgical pathologist, often requiring an extensive immunohistochemical evaluation with variable and frequently unsatisfactory results. In the absence of a history of malignancy, the differential diagnosis of a spindle cell tumor must include both a primary nodal proliferation and a metastatic process. Particularly challenging are those lesions that share morphologic and immunohistochemical features; spindle cell melanomas (SCM) and interdigitating dendritic cell sarcomas (IDCS) belong to this category. At present, electron microscopy is the only method proposed to distinguish between the 2 entities; however, this method is often unavailable and impractical. In this study, we assessed the comparative immunophenotypes of 18 cases of SCM and 8 cases of IDCS, with particular emphasis on the expression of MUM-1, β-catenin, SOX-10, MiTF, and p75. Our results showed nearly equivalent staining patterns and profiles; 12% and 17% of IDCS and SCM were labeled for MUM-1, 75% and 83% stained for β-catenin, 0% and 24% expressed MiTF, and 100% and 94% labeled for p75, respectively. All cases of IDCS and SCM displayed strong nuclear reactivity for SOX-10. On the basis of our study and pertinent literature, the morphologic and immmunophenotypic features of SCM and IDCS appear to be virtually indistinguishable from one another, raising the question as to whether these 2 entities represent a pathobiologically similar or even identical process.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27299798     DOI: 10.1097/PAS.0000000000000678

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Authors:  Fabio Facchetti; Stefano Aldo Pileri; Luisa Lorenzi; Valentina Tabanelli; Lisa Rimsza; Stefania Pittaluga; Stephan Dirnhofer; Christiane Copie-Bergman; Laurence de Leval; Andreas Rosenwald; Andrew Wotherspoon; Falko Fend
Journal:  Virchows Arch       Date:  2017-07-10       Impact factor: 4.064

Review 2.  Interdigitating dendritic cell sarcoma: analysis of two original extra-nodal cases and review of literature.

Authors:  Jiayu Zhou; Qingling Li; Xiaodan Fu; Deyun Feng; Keda Yang; Junpu Wang
Journal:  Virchows Arch       Date:  2022-04-09       Impact factor: 4.064

3.  Retroperitoneal dendritic cell sarcoma: A case report.

Authors:  Chuanhong Wang; Pinggui Lei; Yong Wan; Ping Fu; Bing Fan; Jiaqi Liu; Fangfang Hu; Rongchun Xu
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

4.  Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.

Authors:  Lucas R Massoth; Yin P Hung; Lawrence R Zukerberg; Erik A Williams; Judith A Ferry; Robert P Hasserjian; Valentina Nardi; G Petur Nielsen; Sam Sadigh; Vinayak Venkataraman; Martin Selig; Alison M Friedmann; Wesley Samore; Jonathan Keith Killian; Riza Milante; Joseph Giessinger; Kathleen Foley-Peres; Chelsea Marcus; Eric Severson; Daniel Duncan; Smruthy Sivakumar; Jeffrey S Ross; Vikram Desphande; Shakti H Ramkissoon; Jo-Anne Vergilio; Abner Louissaint
Journal:  Oncologist       Date:  2021-05-06

5.  Spindle cell melanoma: Incidence and survival, 1973-2017.

Authors:  Zhe Xu; Ping Shi; Feiluore Yibulayin; Lei Feng; Hao Zhang; Alimujiang Wushou
Journal:  Oncol Lett       Date:  2018-08-01       Impact factor: 2.967

6.  Expression of the transcription factor ZBTB46 distinguishes human histiocytic disorders of classical dendritic cell origin.

Authors:  Ansuman T Satpathy; Ryanne A Brown; Ellen Gomulia; Carlos G Briseño; Maxwell R Mumbach; Zenggang Pan; Kenneth M Murphy; Yasodha Natkunam; Howard Y Chang; Jinah Kim
Journal:  Mod Pathol       Date:  2018-05-09       Impact factor: 7.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.